Atorvastatin for secondary stroke prevention: An economic evaluation of the SPARCL trial using discrete event simulation

被引：0
|
作者：
Kongnakorn, Thitima
Ward, Alexandra
Roberts, Craig S.
O'Brien, Judith A.
Proskorovsky, Irina
Jaime, J.
机构：
来源：
NEUROLOGY | 2008年 / 70卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A25 / A25
页数：1
相关论文
共 50 条
  • [1] Atorvastatin for secondary stroke prevention: an economic evaluation of the SPARCL trial using discrete event simulation.
    Kongnakorn, Thitima
    Ward, Alexandra
    Roberts, Craig S.
    O'Brien, Judith A.
    Proskorovsky, Irina
    Caro, J. J.
    STROKE, 2008, 39 (02) : 690 - 690
  • [2] Economic Evaluation of Atorvastatin for Prevention of Recurrent Stroke Based on the SPARCL Trial
    Kongnakorn, Thitima
    Ward, Alexandra
    Roberts, Craig S.
    O'Brien, Judith A.
    Proskorovsky, Irina
    Caro, J. Jaime
    VALUE IN HEALTH, 2009, 12 (06) : 880 - 887
  • [3] Atorvastatin is similarly effective in all ischemic stroke subtypes: Secondary analysis of the SPARCL trial
    Amarenco, Pierre
    Benavente, Oscar
    Goldstein, Larry B.
    Callahan, Alfred, III
    Hennerici, Michael G.
    Sillesen, Henrik
    Welch, K. M.
    Zivin, Justin
    STROKE, 2008, 39 (02) : 556 - 556
  • [4] Atorvastatin is similarly effective on all ischemic stroke subtypes: Secondary analysis of the SPARCL trial
    Amarenco, Pierre
    Benavente, Oscar
    Goldstein, Larry B.
    Callahan, Alfred
    Hennerici, Michael G.
    Sillesen, Henrik
    Welch, Michael
    Zivin, Justin
    NEUROLOGY, 2008, 70 (11) : A230 - A230
  • [5] Economic evaluation of Atorvastatin in secondary prevention: an update
    de Portu, Simona
    Montella, Sabato
    Cortesi, Paolo
    Menditto, Enrica
    Cammarota, Simona
    Citarella, Anna
    Mantovani, Lorenzo G.
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2011, 12 : 41 - 52
  • [6] Secondary prevention of stroke according to PRoFESS and SPARCL
    Sander, D.
    Etgen, T.
    INTERNIST, 2009, 50 (11): : 1227 - +
  • [7] Effect of high-dose atorvastatin on changes in renal function: A secondary analysis of the stroke prevention by aggressive reduction of cholesterol levels (SPARCL) trial
    Campese, Vito M.
    Callahan, Alfred, III
    Rudolph, Amy E.
    Messig, Michael
    Amarenco, Pierre
    Goldstein, Larry B.
    Hennerici, Michael
    Sillesen, Henrik
    Zivin, Justin A.
    Welch, K. M.
    CIRCULATION, 2007, 116 (16) : 471 - 471
  • [8] Atorvastatin Reduces the Risk of Cardiovascular Events in Patients With Carotid Atherosclerosis A Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial
    Sillesen, Henrik
    Amarenco, Pierre
    Hennerici, Michael G.
    Callahan, Alfred
    Goldstein, Larry B.
    Zivin, Justin
    Messig, Michael
    Wclch, K. Michacl
    STROKE, 2008, 39 (12) : 3297 - 3302
  • [9] Statins in the secondary prevention of stroke: New evidence from the SPARCL Study
    Castilla-Guerra, Luis
    del Carmen Fernandez-Moreno, Maria
    Manuel Lopez-Chozas, Jose
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2016, 28 (04): : 202 - 208
  • [10] ECONOMIC EVALUATION OF USING HIGH-DOSE ATORVASTATIN FOR THE PREVENTION OF RECURRENT STROKE: EVIDENCE FROM THAILAND
    Suwanwela, N.
    Kongnakorn, T.
    Leartsakulpanitch, J.
    VALUE IN HEALTH, 2010, 13 (07) : A520 - A520
12345